Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Memphasys Ltd ( (AU:MEM) ) has provided an update.
Memphasys has issued 13,253,620 fully paid ordinary shares on 19 December 2025, primarily related to director participation in a Tranche 2 placement and the conversion of directors’ fees into equity at an issue price or deemed issue price of $0.003 per share. The company confirmed that these shares were issued without a prospectus under the Corporations Act’s cleansing provisions, stated it remains compliant with its continuous disclosure and financial reporting obligations, and noted there is no excluded information, effectively clearing the way for secondary trading of the new shares and reinforcing governance transparency for investors.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix System, a patented bio-separation technology used to isolate the most viable sperm cells for human assisted reproduction and IVF. The system combines electrophoresis and size-exclusion membranes to provide a fast, gentle and standardised sperm selection process that aims to improve sperm quality, reduce laboratory time and replace traditional centrifugation methods, with a commercial strategy focused on contracted sales via direct and distribution channels and scaling production to establish Felix as a global standard in sperm preparation.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.07M
See more data about MEM stock on TipRanks’ Stock Analysis page.